Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Int...
Main Author: | Walsh GM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-01-01
|
Series: | Biologics: Targets & Therapy |
Online Access: | http://www.dovepress.com/profile-of-reslizumab-in-eosinophilic-disease-and-its-potential-in-the-a11900 |
Similar Items
-
Severe eosinophilic asthma: therapeutic potential of Reslizumab
by: R. S. Fassakhov
Published: (2018-10-01) -
Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis
by: Milosavljević Miloš N., et al.
Published: (2018-01-01) -
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
by: Sahota J, et al.
Published: (2018-05-01) -
Role of biologics in severe eosinophilic asthma – focus on reslizumab
by: Pelaia G, et al.
Published: (2016-07-01) -
Successful treatment of refractory eosinophilic fasciitis with reslizumab
by: Mahta Mortezavi, MD, et al.
Published: (2020-09-01)